{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T17:15:12Z","timestamp":1776964512387,"version":"3.51.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Bone is considered as the third most common site of metastases, besides lung and liver. Early detection of skeletal metastases aids in better management of skeletal-related events. In the present study cold kit-based 2,2<jats:italic toggle=\"yes\">\u2032<\/jats:italic>,2<jats:italic toggle=\"yes\">\u2032\u2032<\/jats:italic>-(10-(2-((diphosphonomethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid (BPAMD) was labeled with <jats:sup>68<\/jats:sup>Ga. The radiolabeling parameters and clinical evaluation in patients with suspected bone metastases were compared with routinely used <jats:sup>99m<\/jats:sup>Tc-methylenediphosphonate (<jats:sup>99m<\/jats:sup>Tc-MDP).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methodology<\/jats:title>\n            <jats:p>The kit components of MDP were incubated with \n                                    \n                                       \n                                    \n                                  at room temperature for 10\u2009min, followed by radiochemical purity testing using thin-layer chromatography. For radiolabeling of BPAMD, the cold kit components reconstituted in 400\u2009\u03bcL of HPLC grade water were transferred and incubated with <jats:sup>68<\/jats:sup>GaCl<jats:sub>3<\/jats:sub> in the reactor vessel of the fluidic module at 95\u00b0C for 20\u2009min. Radiochemical yield and purity were determined with instant thin-layer chromatography using 0.5\u2009M sodium citrate as mobile phase. For clinical evaluation, patients (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u200910) with suspected bone metastases were enrolled. <jats:sup>99m<\/jats:sup>Tc-MDP and <jats:sup>68<\/jats:sup>Ga-BPAMD scans were performed on two different days in random order. Imaging outcomes were noted and compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Radiolabeling of both tracers is facile using cold kit, although BPAMD requires heating. The radiochemical purity was observed to be greater than 99% for all preparations. Both MDP and BPAMD detected skeletal lesions; however, additional lesions were detected in total of seven patients which were not visualized clearly on <jats:sup>99m<\/jats:sup>Tc-MDP scan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>BPAMD can be easily tagged with <jats:sup>68<\/jats:sup>Ga using cold kits. The radiotracer is suitable and efficient for detection of bone metastases using PET\/computed tomography.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mnm.0000000000001685","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T09:00:18Z","timestamp":1678438818000},"page":"463-470","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of 99mTc-methylenediphosphonate and 68Ga-BPAMD PET\/computed tomography imaging in bone metastasis"],"prefix":"10.1097","volume":"44","author":[{"given":"Rakhee","family":"Vatsa","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damanpreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashank Singh","family":"Shekhar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupriya","family":"Chhabra","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudipta","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh","family":"Dash","sequence":"additional","affiliation":[{"name":"Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaya","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"R1-20250807","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, patho-physiology and treatment strategies.","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"R2-20250807","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/0019-5413.143915","article-title":"Management of skeletal metastases: an orthopaedic surgeon\u2019s guide.","volume":"49","author":"Agarwal","year":"2015","journal-title":"Indian J Orthop"},{"key":"R3-20250807","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.euus.2005.09.006","article-title":"Molecular and biological mechanisms of bone metastasis.","volume":"3","author":"Cecchini","year":"2005","journal-title":"EAU Update Series"},{"key":"R4-20250807","first-page":"321","article-title":"Bone metastases: an overview.","volume":"11","author":"Macedo","year":"2017","journal-title":"Oncol Rev"},{"key":"R5-20250807","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.critrevonc.2005.03.011","article-title":"Management of bone metastases in cancer: a review.","volume":"56","author":"Selvaggi","year":"2005","journal-title":"Clin Rev Oncol Hematol"},{"key":"R6-20250807","first-page":"98","volume":"21","author":"Lukaszewski","year":"2017","journal-title":"Contemp Oncol"},{"key":"R7-20250807","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO clinical practice guidelines.","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"R9-20250807","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0009-9260(69)80174-1","article-title":"The value of fluorine-18 for scanning bone tumours.","volume":"20","author":"Harmer","year":"1969","journal-title":"Clin Radiol"},{"key":"R10-20250807","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/j.semnuclmed.2006.05.001","article-title":"The role of single-photon emission computed tomography\/computed tomography in benign and malignant bone disease.","volume":"36","author":"Horger","year":"2006","journal-title":"Semin Nucl Med"},{"key":"R11-20250807","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40336-016-0196-5","article-title":"Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology.","volume":"4","author":"Cook","year":"2016","journal-title":"Clin Transl Imaging"},{"key":"R12-20250807","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0256-4947.75771","article-title":"18F-FDG PET\/CT imaging in oncology.","volume":"31","author":"Almuhaideb","year":"2011","journal-title":"Ann Saudi Med"},{"key":"R13-20250807","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1148\/radiographics.19.1.g99ja0761","article-title":"Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants.","volume":"19","author":"Shreve","year":"1999","journal-title":"Radiographics"},{"key":"R14-20250807","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2967\/jnumed.117.190157","article-title":"Gallium-68 or fluorine-18 for prostate cancer imaging?","volume":"58","author":"Kesch","year":"2017","journal-title":"J Nucl Med"},{"key":"R15-20250807","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.apradiso.2013.01.039","article-title":"Clinical applications of gallium-68.","volume":"76","author":"Banerjee","year":"2013","journal-title":"Appl Radiat Isot"},{"key":"R16-20250807","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.nucmedbio.2013.04.012","article-title":"In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models.","volume":"40","author":"Meckel","year":"2013","journal-title":"Nucl Med Biol"},{"key":"R17-20250807","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1002\/ejic.200800582","article-title":"Stability constants and dissociation rates of the EDTMP complexes of samarium(III) and yttrium(III).","volume":"30","author":"K\u00e1lm\u00e1n","year":"2008","journal-title":"Eur J Inorg Chem"},{"key":"R18-20250807","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1524\/ract.2011.1791","article-title":"Comparison of different phosphorus-containing ligands complexing 68Ga for PET-imaging of bone metabolism.","volume":"99","author":"Fellner","year":"2011","journal-title":"Radiochim Acta"},{"key":"R20-20250807","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s00259-009-1355-y","article-title":"PET\/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study.","volume":"37","author":"Fellner","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-20250807","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.nucmedbio.2012.04.007","article-title":"68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter.","volume":"39","author":"Fellner","year":"2012","journal-title":"Nucl Med Biol"},{"key":"R22-20250807","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MNM.0b013e32833acb99","article-title":"Optimal buffer choice of the radiosynthesis of (68)Ga-Dotatoc for clinical application.","volume":"31","author":"Bauwens","year":"2010","journal-title":"Nucl Med Commun"},{"key":"R23-20250807","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-022-00180-1","article-title":"Good practices for 68Ga radiopharmaceutical production.","volume":"7","author":"Nelson","year":"2022","journal-title":"EJNMMI Radiopharm Chem"},{"key":"R24-20250807","first-page":"217","article-title":"Integrin \u03b1v\u03b23 as a promising target to image neoangiogenesis using in-house generator-produced positron emitter (68)Ga-labeled DOTA-arginine-glycine-aspartic acid (RGD) ligand.","volume":"30","author":"Vatsa","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"R25-20250807","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1148\/radiographics.13.4.8356264","article-title":"Extraosseous Tc-99m MDP uptake: a pathophysiologic approach.","volume":"13","author":"Peller","year":"1993","journal-title":"Radiographics"},{"key":"R26-20250807","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice.","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"R27-20250807","first-page":"18","article-title":"Radiopharmaceuticals for bone lesions. Imaging and therapy in clinical practice.","volume":"45","author":"Pauwels","year":"2001","journal-title":"Q J Nucl Med"},{"key":"R28-20250807","first-page":"472","article-title":"DOTAZOL as novel bone seeking compound for Ga-68 PET diagnosis and Lu-177 endoradiotherapy of bone metastases: from preclinical to first human results.","volume":"57","author":"Pfannkuchen","year":"2016","journal-title":"J Nucl Med"},{"key":"R29-20250807","first-page":"94","article-title":"Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy.","volume":"30","author":"Meckel","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"R30-20250807","first-page":"1164","article-title":"177Lu-BPAMD \u2013 from bone imaging to therapy with a macrocycle-bisphosphonate ligand.","volume":"51","author":"Fellner","year":"2010","journal-title":"J Nucl Med"},{"key":"R31-20250807","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0969-8051(21)00431-5","article-title":"Formulation and evaluation of human clinical doses of 177Lu-labeled bisphosphonate amide of DOTA using lyophilized kits.","volume":"96-97","author":"Chakraborty","year":"2021","journal-title":"Nucl Med Biol"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:05:36Z","timestamp":1754597136000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000001685","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,10]]}}}